McDermott and Bull executive Search

Other News

Catasys Announces Expansion of OnTrak-A Solution to Florida and Georgia with Leading National Health Plan

LOS ANGELES–(BUSINESS WIRE)–Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that it has expanded its OnTrak-A solution into Florida and Georgia with one of the nation’s leading health plans. This follows OnTrak-A’s expansion into Iowa and Nebraska earlier this month. Eligible […]

Alucent Biomedical Announces Formation of Scientific Advisory Board

SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical, a privately held biotechnology company founded to transform the way vascular disease is treated, today announced the formation of its scientific advisory board with seven key appointments: Gary Ansel, M.D.; Elazar Edelman, M.D., Ph.D.; William Gray, M.D.; Larry Kraiss, M.D.; Krishna Rocha-Singh, M.D.; William Sessa, Ph.D. and Craig […]

CathWorks FFRangio™ Trial Meets Primary Endpoint and Exceeds Performance Goals

KFAR-SABA, Israel–(BUSINESS WIRE)–The journal Circulation published results from the CathWorks FFRangio™ FAST-FFR clinical trial in an article titled Accuracy of Fractional Flow Reserve Derived From Coronary Angiography. The publication and trial results were announced today at the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego, California. The FAST-FFR trial demonstrated that the […]

Stereotaxis to Present at OTCQX Virtual Investor Conference for Domestic Companies

ST. LOUIS, Mo., Sept. 25, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will present at the OTCQX Virtual Investor Conference for Domestic Companies. Management will provide an overview of the Company’s technology […]

Orchestra BioMed™ Announces Presentation of Positive 2-Year Clinical Results and Program Update for BackBeat® Cardiac Neuromodulation Therapy at TCT 2018

SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, presented positive 2-year clinical results from its multicenter clinical trial for BackBeat® Cardiac Neuromodulation Therapy (CNT) at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 in San […]

TARA Biosystems’ Groundbreaking Biowire™ II Heart-on-a-Chip Platform Earns Acclaim from Frost & Sullivan

SANTA CLARA, Calif., Sept. 25, 2018 /PRNewswire/ — Based on its recent analysis of the North American heart-on-a-chip market, Frost & Sullivan recognizes TARA Biosystems with the 2018 North American Technology Innovation Award for its trailblazing Biowire™ II heart-on-a-chip platform. This solution produces mature, engineered, human cardiac tissues and demonstrates promise as a valuable […]

Positive Data On BioCardia’s Investigational CardiAMP Cell Therapy For Heart Failure Presented At Transcatheter Cardiovascular Therapeutics (TCT) Conference

SAN DIEGO and SAN CARLOS, Calif., Sept. 24, 2018 /PRNewswire/ — BioCardia®, Inc. (OTC :BCDA ), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that positive data from two studies of its investigational CardiAMP stem cell therapy were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) conference. CardiAMP cell therapy […]

Landmark Lipid-Rich Plaque (LRP) Study Results Demonstrate the Ability to Accurately Identify Patients and Plaques at Risk for Major Coronary Events

BURLINGTON, Mass.–(BUSINESS WIRE)–Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, presented late-breaking clinical trial results for its landmark Lipid-Rich Plaque (LRP) Study today at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. Cardiovascular disease remains the number one cause […]

Cardiovalve Announces AHEAD US Study for Transcatheter Mitral Valve Replacement System

OR YEHUDA, Israel, Sept. 20, 2018 /PRNewswire/ — Cardiovalve announced today that it has commenced the AHEAD USmulticenter study (U.S. Early Feasibility Study of High Surgical Risk Patients with Severe Mitral Regurgitation Treated with the Cardiovalve Transfemoral Mitral Valve System). AHEAD US trial recruitment will start in early Q4 2018. The primary endpoint of the […]